

Journal Pre-proofs

Fabrication of *Ligusticum chuanxiong* polylactic acid microspheres: A promising way to enhance the hepatoprotective effect on bioactive ingredients

Huifang Ge, Peixuan Lin, Taiduan Luo, Zhiming Yan, Jianbo Xiao, Song Miao, Jicheng Chen

PII: S0308-8146(20)30235-1

DOI: <https://doi.org/10.1016/j.foodchem.2020.126377>

Reference: FOCH 126377

To appear in: *Food Chemistry*

Received Date: 6 October 2019


Revised Date: 30 December 2019

Accepted Date: 8 February 2020

Please cite this article as: Ge, H., Lin, P., Luo, T., Yan, Z., Xiao, J., Miao, S., Chen, J., Fabrication of *Ligusticum chuanxiong* polylactic acid microspheres: A promising way to enhance the hepatoprotective effect on bioactive ingredients, *Food Chemistry* (2020), doi: <https://doi.org/10.1016/j.foodchem.2020.126377>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.



1 **Fabrication of *Ligusticum chuanxiong* polylactic acid microspheres:**
2 **A promising way to enhance the hepatoprotective effect on bioactive**
3 **ingredients**

4 Huifang Ge¹, Peixuan Lin¹, Taiduan Luo¹, Zhiming Yan¹,

5 Jianbo Xiao¹, Song Miao^{1,2,3*}, Jicheng Chen^{1,2*}

6 ¹ *College of Food Science, Fujian Agriculture and Forestry University, Fuzhou, China*

7 ² *China-Ireland International Cooperation Center for Food Material Science and Structure*

8 *Design, Fujian Agriculture and Forestry University, Fuzhou, China*

9 ³ *Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland*

10

11 *Corresponding author:

12 Dr. Jicheng Chen

13 Tel: +86-591-8378-9348

14 Fax: +86-591-8378-9348

15 E-mail: newtaicjc@163.com

16 Prof. Song Miao

17 Teagasc Food Research Centre, Moorepark, Ireland

18 Tel: +353 25 42468

19 Fax: +353 25 42340

20 Email: song.miao@teagasc.ie

21 **Abstract**

22 *Ligusticum chuanxiong* extract-poly(lactic acid) sustained-release microspheres
23 (LCE-PLA) are fabricated in this study for enhancing both duration and
24 hepatoprotective efficacy of the main bioactive ingredients. LCE-PLA *in vitro* release,
25 cytotoxicity and *in vivo* hepatoprotective effect were discussed to evaluate its
26 efficiency and functionality. Results demonstrated that the optimal drug-loading rate
27 and encapsulation efficiency of tetramethylpyrazine (TMP, the main active
28 ingredient) were 8.19%, 83.72%, respectively. The LCE-PLA *in vitro* release of TMP
29 showed prolong 5-fold and *in vitro* cytotoxicity declined 25.00% compared with
30 naked LCE. After 6 weeks of *in vivo* intervention in high fat diet mice, both liver
31 aspartate aminotransferase and alanine aminotransferase levels were higher in
32 LCE-PLA group than LCE group. The above results indicated that TMP had a higher
33 bioavailability of hepatoprotection when encapsulation of LCE-PLA was applied. The
34 current study has provided a promising novel way to enhance the efficacy of short
35 half-life ingredients.

36 **Keywords:** *Ligusticum chuanxiong*, sustained-release, microspheres, high fat diet,
37 hepatoprotective effect

39 1 Introduction

40 Long-term intake of high fat food (HFD) increases the body weight and results in
41 obesity, and in turn causes serious damage to the liver like fatty liver and cirrhosis
42 even hepatocellular carcinoma (Qin, Zhao, Zhou, Zhang, Wen, Tang, et al., 2018).
43 Dietary **therapy** has been recommended for treatment of liver disease, especially for
44 the cirrhosis and nonalcoholic fatty liver disease (Mager, Iniguez, Gilmour, & Yap,
45 2015). **Natural herbal** dietary supplements are the most popular pathway due to its
46 complex mechanisms as multi-compound, multitarget and multi-pathway
47 (Brodziak-Dopierala, Fischer, Szczelina, & Stojko, 2018; Wang, Li, Zhao, Liu, Liu,
48 Yang, et al., 2013). **Traditional hepatic-protecting herbal plants, such as *Ligusticum***
49 ***chuanxiong*, *Salvia*, *Angelica*, *Panax notoginseng*, *Astragalus*, etc., have been**
50 **reported to reduce serum aminotransferase degeneration and necrosis of liver cells**
51 **and show anti-fibrosis effect (Gao, 2013).**

52 **Ligustrazine, also known as tetramethylpyrazine (TMP), is the major alkaloid in**
53 ***Ligusticum chuanxiong*. TMP, with a simple structure, is well studied because of its**
54 **multiple significant biological functions, such as inhibiting apoptosis, dilating blood**
55 **vessels, protecting vascular endothelial cells and immune regulation, eliminating**
56 **oxygen free radical, improving cerebral ischemia, inhibiting platelet aggregation, and**
57 **promoting angiogenesis, effectively attenuate liver injury etc. (Mo, Liu, Li, Xu, Wen,**
58 **Xian, et al., 2017; Yu, Guo, Zhang, Liu, Zou, Fu, et al., 2016). TMP has been**
59 **extensively used for developing health-promoting foods.**

60 **However, the shortcoming of fast metabolism, short half-life (1.62 h), and poor**

61 oral availability limit TMP application in liver therapy (Li, Song, Zhu, Yin, Ji, Li, et
62 al., 2014). Sustained-release microspheres have been reported to help prolong the
63 acting time of medicament, improve patient compliance and reduce side effects (Wu,
64 Hu, & Jin, 2016). In addition, the majority studies on the sustained-release
65 microspheres are based on the *in vitro* experiments such as antioxidant and cytoactive,
66 but rare evaluation on the *in vivo* function and cytotoxicity. In this study, *Ligusticum*
67 *chuanxiong* extract (LCE) was used to make sustained-release microspheres to
68 enhance its bioavailability and efficiency of hepatoprotective.

69 Polylactic acid (PLA), as a biodegradable polymer with the characteristic of high
70 elastic modulus, high mechanical strength, and feasible processability, has been
71 widely used in the preparation of slow-controlled release microspheres, especially in
72 the preparation of composite microspheres (Surwase, Munot, Idage, & Idage, 2017).
73 Traditional emulsion solvent evaporation method has been widely used to encapsulate
74 hydrophilic drugs in polymeric particles (Murphy & Lampe, 2018). LCE can be
75 soluble in water, W/O/W (water-in-oil-in-water) multiple emulsion technique is a
76 useful method for water-soluble drug encapsulation (Bodmeier, Wang, &
77 Bhagwatwar, 1992).

78 In the present study, LCE was incorporated in W/O/W multiple emulsions with
79 PLA as the carrier material, tween-80 and PVA as the co-emulsifier. The technologies
80 for encapsulating LCE were optimized and the microspheres were characterized with
81 the drug-loading rate (DL), encapsulation efficiency (EE), morphology and *in vitro*
82 cytotoxicity. Swelling ratios of the microspheres at different pH was evaluated for

83 unveiling the mechanism of the *in vitro* release profiles. Furthermore, the
84 hepatoprotective effects in mice were evaluated. The outcome will favor the
85 application of *Ligusticum chuanxiong* on liver therapy.

86 **2 Materials and methods**

87 **2.1 Materials**

88 *Ligusticum chuanxiong* (origin: Sichuan, the production license: 20160084).
89 TMP standard (purity \geq 99.98%) was purchased from Shanghai Yuan ye
90 Biotechnology Co. Ltd. Polyvinyl alcohol 124 (PVA, 1.05×10^5 Da). **Chemical pure**
91 Tween-80, **analytical reagent** dichloromethane (DCM), **analytical reagent** methanol,
92 $\text{NaH}_2\text{PO}_4 \cdot 2\text{H}_2\text{O}$, $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ and potassium bromide were purchased from
93 Sinopharm Chemical Reagent Co., Ltd. Polylactic acid powder (4500 Da) was
94 purchased from America Nature Works. The defoaming agent (WH-Z) was purchased
95 from Changzhou Jiangdong auxiliaries Co., Ltd.; Total triacylglycerols (TG),
96 Cholesterol (TC), Aspartate aminotransferase (**AST**) and Alanine aminotransferase
97 (**ALT**) kits were purchased from Nanjing Jiancheng Biological Engineering Institute.

98 **2.2 Preparation of *Ligusticum chuanxiong* extraction**

99 Using 95% ethanol to reflux extraction 100.00 g *Ligusticum chuanxiong* powders
100 (1:8, w/v) for 2 times and then freezing dried the extraction liquid for further use.

101 **2.3 Preparation of LCE-PLA**

102 *Ligusticum chuanxiong* extract-poly(lactic acid) sustained-release microspheres
103 (**LCE-PLA**) were prepared through the emulsion solvent evaporation technique
104 (Petkar, Chavhan, Kunda, Saleem, Somavarapu, Taylor, et al., 2018). LCE was

105 dissolved in distilled water (10 mg/mL) at 40 °C to prepare the internal water phase
106 (W_1). The oil phase (O) was prepared by mixing PLA with DCM (PLA/DCM, w/v)
107 and stirring for 30 min at 24 °C. The external aqueous phase (W_2) was prepared by
108 adding PVA and Tween-80 (co-emulsifier) and shearing with a homogenizer at 9000
109 rpm for 2 minutes.

110 Phase W_1 was added dropwise into the organic phase (O) to make W_1/O primary
111 emulsion. $W_1/O/W_2$ composite emulsion was herein obtained by adding phase W_2
112 into the primary emulsion. The composite emulsion was homogenized to prepare
113 stable multiple emulsions. After that, the organic phase was vaporized at 40 °C to get
114 solid microspheres. The produced microspheres were collected by centrifugation at
115 6,000 rpm, washed thrice with distilled water, and lyophilized overnight (Surwase,
116 Munot, Idage, & Idage, 2017).

117 **2.4 Determination of drug-loading rate and entrapment efficiency**

118 TMP in LCE were quantified by high performance liquid chromatography
119 (HPLC) according to our previous method (Ge, Chen, Chen, Tian, Liang, & Chen,
120 2018). In brief, Waters XBridge C18 reversed phase column (600 Bar, 250mm×4.6
121 mm, 5 μ m) was used for chromatographic analysis. The mobile phase is methanol:
122 1% glacial acetic acid aqueous solution= 45:55; velocity of flow is 0.80 mL/min;
123 detection wavelength: 310 nm. Content of TMP in LCE is 55.69 mg/g.

124 The DL and EE of TMP in microsphere were determined by the above HPLC
125 method after the following pretreatment steps. Firstly, ten mg of microspheres was
126 suspended in 10 mL of methanol and subjected to ultrasonic treatment at 80 W for 10

127 min and centrifuged the mixture at 10000 rpm for 10 min. Secondly, taken 1 mL
128 supernatant were diluted to 10 mL with methanol and **filtered through 0.22 mm**
129 **membrane before determination**. The DL and EE were calculated by following
130 equations (Duan, Zhang, Chu, Tong, Liu, & Zhai, 2016):

$$131 \quad DL = \text{Weight of TMP in microspheres} / \text{Mass of microsphere} \times 100\% \quad (1)$$

$$132 \quad EE = \text{Drug encapsulated in microspheres} / \text{Weight of drug added} \times 100\% \quad (2)$$

133 **2.5 Optimization preparation of LCE-PLA**

134 PLA concentrations (20, 30, 40, 50 and 60 mg/mL), PVA contents (0.60%,
135 0.80%, 1.00%, 1.20% and 1.40%), shearing times (2, 3, 4, 5 and 6 min) and shearing
136 speeds (7000, 8000, 9000, 10000 and 11000 rpm) were set as the factors to investigate
137 the DL and EE of TMP in composite microspheres. During the preparation, Tween-80
138 and PVA was used as a co-emulsifier, the scale of W_1 and W_2 was 1:20. The
139 evaporation rate of solvent was set at 300 rpm for 4 h.

140 **2.6 Fourier transform infrared spectroscopy analysis**

141 Fourier transform infrared (FT-IR) spectra of pure PLA, LCE and LCE-PLA
142 obtained on a WQF-510 spectrometer (Campardelli, Oleandro, & Reverchon, 2016).
143 Each sample was prepared in KBr discs (1.00%, w/w), and the scans were conducted
144 over the range from 4000-400 cm^{-1} . For each spectrum, 64 scans with air as the
145 background were obtained at a resolution of 4 cm^{-1} . Spectra over the range of
146 4000-400 cm^{-1} were baseline corrected automatically, normalized and deconvoluted.

147 **2.7 Morphology and particle size of microspheres**

148 The morphology of LCE-PLA was observed by scanning electron microscopy

149 (SEM) (Petkar, et al., 2018). Samples were mounted onto the metal holder and gold
150 coated in a vacuum chamber, then recorded images at 15 KV acceleration voltage by
151 JSM-6380LV SEM (JSM-6380LV, JEOL, Tokyo, Japan).

152 The mean particle size of the W/O/W microsphere was measured by a laser
153 particle-size analyzer (Beckman, Brea, CA, USA). The dry microspheres were placed
154 in deionized water and stirred at 3000 rpm and sonicated at 50 mV until the
155 light-blocking ratio between 5%-13%. Each sample measure three times. Afterwards,
156 analyses the particle size of the W/O/W microspheres by the software provided. The
157 median of particle size ($D_{50} \pm SD$) was reported as the particle size of microspheres
158 (Bagheri-Khoulenjani, Etrati-Khosroshahi, & Mirzadeh, 2010).

159 **2.8 *In-vitro* drug release and swelling ratio**

160 LCE-PLA *in-vitro* release behaviors were determined according to the method of
161 Surwase, Munot, Idage and Idage (2017). Fifty mg of microspheres was suspended in
162 different phosphate buffer solutions (pH 1.2, pH 6.8, pH 7.4) to make the
163 microspheres solution, then put the solutions into 3 dialysis bags (MW, 14000 Da)
164 (Lin, Huo, Qin, Zhao, & Tao, 2017). Afterwards, the dialysis bags were put into 28
165 mL phosphate buffer (pH 1.2, pH 6.8, pH 7.4) and maintained at 37 ± 1 °C with 100
166 rpm agitating for 10 hours. Withdraw 3 mL aliquots every half an hour, and an equal
167 volume was replaced with fresh phosphate buffer each time and then determined at
168 279 nm. Finally, quantify the released of drugs, and demonstrated the cumulative
169 release profile with time at different pH conditions. All measurements were
170 performed in three replicates, and results expressed as mean value \pm SD.

171 Swelling capacity of LCE-PLA at different pH (pH 1.2, pH 6.8, pH 7.4) were
172 measured based on the method of Khattab and Zaki (2017). Three portions of
173 lyophilized microspheres (each portion of 100 mg) were placed in pre-weighed dense
174 gauze bag and weighed (W_0), then put the bags into different mediums. Taken out the
175 bags every 0.5 h, filter paper was then used to absorb the water attached to the
176 microsphere surfaces, then weighted to get the wet microspheres weight (W_t) until the
177 mass of microspheres keeps constant. Each pH situation was performed in three
178 replicates. The swelling ratio (SR) was calculated as following equation:

$$179 \quad SR = (W_t - W_0) / W_0 \times 100\% \quad (3)$$

180 2.9 Cytotoxicity assay

181 To ensure the safety of the LCE-PLA, the cytotoxicity was measured following
182 the method by Chen et al. (Chen, Tian, Ge, Liu, & Xiao, 2017; Yoon & Liu, 2007).
183 Density of 4×10^4 /well HepG2 cells and 100 μ L growth medium were plated into a
184 96-well plat and incubated at 37 °C for 24 h. **After removing the growth medium, the**
185 **cells were treated with 100 μ L fresh medium (WME supplemented with 2 mM**
186 **L-glutamine and 10 mM HEPES) with different concentrations of TMP, LCE, and**
187 **LCE-PLA as samples or only Dimethyl sulfoxide (DMSO) as control for another 24 h**
188 **at 37 °C.** After that, each well was added 50 μ L methylene blue solution, which
189 contained by 98.00% HBSS, 0.67% glutaraldehyde, 0.60% methylene blue, the plat
190 was stored at 37 °C for 1 h. Using water to rinse the cells until the water was clear and
191 then dried cells. The elution solution, consisting of 49.00% PBS, 50.00% ethanol and
192 1.00% acetic acid, were used to elute the methylene blue stain for 1 h at room

193 temperature. Finally, the absorbance was read at 570 nm with blank subtraction by an
194 MRX II Dynex plate reader (Dynex Technologies, Inc., Chantilly, VA).
195 Concentrations of the LCE-PLA or LCE or pure TMP that decreased the absorbance
196 by more than 10.00% were considered cytotoxic compared with the control group. In
197 the present study, the contents of TMP in LCE and LCE-PLA were equal to the pure
198 TMP group.

199 **TMP stock solutions which concentration below 0.5 mg/ml were directly**
200 **prepared by fresh medium, the concentration exceeded 0.5 mg/ml were dissolved in**
201 **fresh medium contain 1% DMSO.**

202 **2.10 Animals and experimental design**

203 Forty male Kunming mice weighing 20.00 ± 2 g were purchased from the
204 Beijing HFK Bioscience CO..LTD (SCXK 20140004). The mice were housed in
205 Animal Center of Fuzhou General Hospital of Nanjing Military Command at a
206 constant temperature of 25 °C and humidity range of 50-60% with a 12-h light/dark
207 cycle. After acclimatization for one week, the mice were randomly divided into two
208 groups. The first group (normal-fat diet, NFD) is the normal, healthy control group (8
209 mice) and the second group (Group II) is the HFD group (32 mice). During the
210 6-week experimental period, all mice in group II were fed with HFD (containing
211 5.00% sucrose, 10.00% lard oil, 2.00% cholesterol, 0.50% bile salts, 0.20% propyl
212 thiouracil, 5.00% whole yolk powder, 5.00% bentonite and 72.30% NFD). Both NFD
213 and HFD were provided by Beijing Keao Xieli Feed Co. Ltd.

214 Mice in group II were further classified into four groups: group II-a (HFD),

215 group II-b (HFD+S, commercial *Simvastatin* treated group at a dose of 6.00 mg/kg
216 B.w./Day), group II-c (HFD+LCE, *Liguticum chuanxiong* alcohol extract treated
217 group at a dose of 136.50 mg/kg B.w./Day) and group II-d (HFD+DM, drug-loading
218 microspheres treated group at a dose of 163.00 mg/kg B.w./Day). In the current study,
219 the LCE feeding dose was calculated according to the daily consumption (10.00
220 g/day) of *Liguticum chuanxiong* crude rhizome recommended by Chinese medicine,
221 and the extraction yield of LCE is about 9.10%. The dose of TMP in microspheres
222 (EE of TMP 83.72%) was equal to which in LCE. Simvastatin as a positive common
223 drug for treat hyperlipidemia, its dose was according to the clinic recommended by
224 the instructions (Guo, Pan, Li, Li, Liu, & Lv, 2018).

225 At the end of the experiment, all mice were injected intraperitoneally with 40
226 mg/kg pentobarbital sodium, then collected blood samples from the abdominal aorta
227 and centrifuged at 3000 g for 10 min to separate serum and stored at -20 °C. After
228 that, all mice were sacrificed by cervical dislocation and dissected. The livers were
229 quickly removed and washed with physiological saline and blotted dry on filter paper,
230 partial liver tissues were taken for hepatic histological analysis by Hematoxylin-Eosin
231 Stain (HE) (Guo, Pan, Li, Li, Liu, & Lv, 2018).

232 **2.11 Statistical analysis**

233 One-way analysis of variance (ANOVA) was performed with Tukey's HSD test
234 ($p < 0.05$) using SPSS (17.0 version, IBM). All results were expressed as mean \pm
235 standard deviation. The significance level was set as $p < 0.05$.

236 **3 Results and discussion**

237 3.1 Preparation optimization of LCE-PLA

238 Research had found that different preparation process could affect the
239 encapsulation rate of active ingredients (Ebrahimi, Saffari, & Langrish, 2017; Qiu,
240 Zheng, Fang, Wang, Min, Shen, et al., 2018). As indicated in **Table S1**, with the
241 increased of PVA addition level (PVA/Water, w/v), both DL and EE of TMP reached
242 the maximum value at 6.83% and 69.91%, respectively. When the addition of PVA
243 was greater than 0.80%, results of DL and EE showed no significant difference
244 ($p>0.05$). Therefore, the addition of PVA was selected by 0.80% (PVA/Water, w/v).
245 When the concentration of PLA increased to 40 mg/mL, effect of PLA addition on the
246 DL and EE showed no significant difference ($p>0.05$). To save energy, the
247 concentration of PLA was selected 20 mg/mL. Effect of shearing time on the DL and
248 EE were significant difference in **Table S1** ($p<0.05$). During the first 4 minutes, both
249 DL and EE increased with the increase of shearing time. Interestingly, after 4 minutes,
250 with the prolonger of shearing time, results of the DL and EE showed no significant
251 difference ($p>0.05$). Influences of shearing force on the DL and EE were significant
252 differences ($p<0.05$) in **Table S1**. With the increase of shearing force, the emulsion
253 sizes become smaller, and the contact area is increased, thus, the DL and EE are
254 increased. When the shearing force more than 1000, there was no significant different
255 ($p>0.05$), thus chosen the shearing fore at 10000 rpm. To sum up, the reasonable
256 preparation process is the PLA concentration of 20 mg/mL (PLA/DCM, w/v), PVA
257 0.80% (PVA/Water, w/v), and shearing force at 10000 rpm for 4 min.

258 3.2 FT-IR spectroscopy

259 FT-IR spectroscopy was carried out to characterize the interaction mechanism of
260 LCE loaded in PLA microspheres. As illustrated in **Fig. 1**, the characteristic peaks
261 around 3524 cm^{-1} and 3251 cm^{-1} (hydrogen bonds from -OH), as well as 1421 cm^{-1}
262 (stretching vibration of C=O), 1665 cm^{-1} (stretching vibrations of -C=N) and 992 cm^{-1}
263 (C=C) in LCE, disappeared in the LCE-PLA microspheres attributing to the adequate
264 encapsulation process (Zou, Fu, Chen, Austarheim, Inngjerdingen, Huang, et al.,
265 2017). The characteristic peaks at 1391 cm^{-1} (stretching vibration of -CH₃), 1756 cm^{-1}
266 (stretching vibration of C=O) and 1095 cm^{-1} (C-O-C) in PLA (Garlotta, 2001;
267 Yuniarto, Purwanto, Purwanto, Welt, Purwadaria, & Sunarti, 2016) were sharply
268 attenuated in the LCE-PLA microspheres might due to the interaction with LCE.
269 Interestingly, the typical band of PLA at 2369 cm^{-1} (stretching vibration of C=O) was
270 also disappeared in the LCE-PLA microspheres resulting from the interaction with
271 LCE, which confirmed the internalization of C=O in PLA during the formation of
272 microspheres.

273 3.3 Surface morphology of microspheres

274 Mlalila, Swai, Kalombo and Hilonga (2014) found that higher emulsifier
275 concentrations would decrease the interfacial tension via facilitating particle
276 disruption. When PVA concentrations increased, the surfactants may form tighter
277 micelles around microspheres, and resulted in the small size (Xu, Zhong, Liu, Xu, &
278 Gao, 2011). In **Fig. 2 C**, the particle sizes of microspheres were surely smaller than
279 that of **A**. In the **Table S1**, with the concentration of PVA (PVA/water, v/v) increased,
280 the particle size (D_{50}) declined from $18.78\text{ }\mu\text{m}$ to $10.50\text{ }\mu\text{m}$, those results were in

281 agreement with the result of Li et al. (2013). When the PVA concentration increased,
282 the surfactants might closely to form tighter micelles around the microspheres, which
283 result in a smaller particle size. However, with the concentration of PLA increased,
284 the mean particle sizes of microspheres increased from 11.41 μm to 17.90 μm in
285 Table1, which can also be found in Fig. 2 B.

286 The resultant product by high-shear shows a smaller particle size compared with
287 the emulsion produced by the conventional agitation (Patrick & James, 1997).
288 Different speed resulted in the different particle size of microspheres, with the
289 increasing of shearing speed, the particle size became smaller in Fig. 2 D. When
290 shearing time increased, microspheres sizes were also declined in Fig. 2 E.
291 Bagheri-Khoulenjani, Etrati-Khosroshahi and Mirzadeh (2010) found that high speed
292 could help to decline the size of microspheres.

293 SEM imaging of empty microspheres and broken microspheres were also studied
294 (Fig. S1 A, C). The broken microspheres were prepared by a high temperature and
295 high-pressure reactor (HTLAB). LCE-PLA was basically round, but slightly
296 deformed when compared with the empty microspheres, this might be the cause of
297 LCE combined into microspheres added the weight of microspheres. The broken
298 microspheres SEM photographs were used to imitate the state of the microspheres
299 after fully swelled and ruptured in the body (Chu, Liu, & Chen, 2018).

300 Both Tween-80 and PVA is commonly used as emulsifier in preparation
301 microspheres. The research found that the co-emulsifier can help improving
302 emulsifying performance (Zhang & Haque, 2015). In the present study, Tween-80 and

303 PVA is used as the co-emulsifier to help enhance the quality of microspheres. Due to
304 its high viscosity in aqueous solution, strong adsorption around the surfaces of the
305 emulsion droplets, PVA could help make a smooth-surface and spherical morphology
306 of microspheres (Feng & Huang, 2001) like the microspheres in **Fig. 2** and **Fig. S1**.

307 **3.4 Microspheres swelling and ratio *in-vitro* drug release**

308 As illustrated in **Fig. 3 A**, the *SR* of microspheres increased following by time
309 under different medium. At 3 h, the S_{Max} value is 11.82% (pH 1.2), 15.02% (pH 6.8),
310 and 16.19% (pH 7.4), respectively. Microspheres can be swelled well during the weak
311 acidic and weak basic conditions. When the medium pH at 1.2, the *SR* increased
312 slower compared with the other two mediums. Reports had found that process of
313 swelling was related to the ionization and the protonation balance of the carboxyl
314 groups. TMP mainly absorbed in the small intestine, during those conditions, the
315 -COOR of PLA can slowly react with the basic condition solution (Metters, Anseth,
316 & Bowman, 2000). TMP can be released in the intestine condition absolutely and
317 prolonged the half-life.

318 The accumulative releasing rate of TMP in LCE-PLA under different pH media
319 (pH 1.2, pH 6.8, pH 7.4) were shown in **Fig. 3 B**, the release could be sustained at
320 least 10 h. Comparing with the TMP half-life, the microspheres duration of efficacy
321 prolonged nearly 5-fold. Generally, the hydrolytic mechanism was considered as the
322 mechanism of degradation of aliphatic polyester microspheres (Pistner, Bendix,
323 Mühling, & Reuther, 1993) With the penetration of water, the prepared W/O/W PLA
324 microspheres were substantially bulk erosion, degraded, and followed with the slow

325 diffusion of encapsulated drug, those results were consistent with the reports by Ford
326 Versypt et al. (Ford Versypt, Pack, & Braatz, 2013; Li, Wang, Yu, Bao, & Li,
327 2013). The prepared microspheres were first swelling in each condition solution,
328 during this process, because of the ionization and the protonation balance of the
329 carboxyl groups, the carrier material PLA can be absolutely hydrolysis especially in
330 the weak basic conditions and released the activity compounds (Metters, Anseth, &
331 Bowman, 2000). The *SR* of microspheres was reached to the highest at 3 h in **Fig. 3 A**
332 and result in a high-speed release in **Fig. 3 B**. After 2 h, the cumulative releasing rate
333 was reached to 38.00% of the median of pH 1.2 while the rate was over 50.00% at pH
334 6.8 and pH 7.4. At 6 h, there was no significant difference in the release rate of
335 microspheres between pH 6.8 and pH 7.4 ($p>0.05$). Result suggested that during the
336 environment of weak acid or a weak base, the microspheres could be dissolved as
337 well, which also indicated that the W/O/W composite microspheres could prolong the
338 time of drug action. Research has found that a single administration of drug-loaded
339 polymer microsphere could help the release of drug in a long period by the way of
340 continuous and controlled, therefore, the drug concentration could retain in the within
341 target (Ma, Yuan, Kang, Su, Yuan, Pu, et al., 2008).

342 **3.5 Result of cytotoxicity and hepatotoxicity**

343 Cytotoxicity as a significant criterion has been widely used to determine the
344 suitability of polymers in drug delivery (Petkar, et al., 2018). In this paper, there were
345 no significant difference in percent cell viability of LCE-PLA compared to the LCE,
346 pure TMP and control group when the drug concentration below 0.8 mg/mL in **Fig. 4**.

347 The cytotoxicity of pure TMP, LCE and LCE-PLA became evident at the
348 concentration of 1.50 mg/mL, 0.80 mg/mL, and 1.00 mg/mL, respectively.
349 Cytotoxicity of LCE was declined 25.00% compared with LCE. Coowanitwong,
350 Arya, Kulvanich and Hochhaus (2008) found that Rifampin-PLA microsphere
351 formulations were low cytotoxicity.

352 To investigate the hepatotoxicity of treatment contents, the hepatic TG, hepatic
353 TC AST, ALT and hepatic histopathology of liver and kidney in all groups were
354 determined. As shown in **Fig. 5 A**, the HFD groups mice hepatocytes were markedly
355 swollen and enlarged, and it was easy to find that the hepatic nuclei were compressed
356 to side and there were many fat vacuoles in the cytoplasm. In contrast, simvastatin,
357 LCE and microspheres treatment improved the cellularity of liver cells, and smaller
358 lipid droplets were observed compared with HFD. The liver weight in HFD, HFD+S,
359 HFD+LCE, HFD+DM groups was increased in **Table 1** compared with NFD group.
360 The values of the above group livers weight Δa (%), Δb (%), Δc (%) and Δd (%)
361 in **Table 1** was 31.34, 10.45, 24.88 and 11.44, respectively. Report had found that
362 the increase of liver coefficient could indicate edema, inflammation, or hyperplasia in
363 the liver tissue (Bezan, Mrsic, Krieger, Stojakovic, Pummer, Zigeuner, et al., 2015).
364 Results indicated that LCE-PLA had a helpful effect on the liver injury mice induced
365 by HFD. And the effect of above treatment activity compounds followed as:
366 Simvastatin > LCE-PLA > LCE. **Fig. 5 B** showed the histological analysis of kidney
367 sections. In the treatment group, the renal tubules were clear and the cells arranged
368 regularly while the HFD group showed the opposite situation such as narrowing of the

369 renal tubule, cells fusion and glomerulonephritis. In **Table 1**, NFD group and
370 treatment groups had the same kidney weight, those mice kidney were normal.

371 AST and ALT are well-known liver enzymes produced by both malignant and
372 non-malignant cells and have been widely used in the evaluation of various causes of
373 liver disease such as viral hepatitis and alcohol abuse etc. (Bezan, et al., 2015; Lee,
374 Lee, Byun, Kim, Kwak, & Hong, 2017). In **Fig. 5 C**, the value of hepatic TG and TC
375 in HFD group were higher than which in treatment groups, while the AST and ALT
376 showed the opposite ($p<0.01$). When the liver injury, the AST and ALT will be
377 released into the blood and reduced the content in liver tissue. In the current study, in
378 each treatment group, levels of both AST and ALT were as follows:
379 NFD>HFD+S>HFD+DM>HFD+LCE. The above results confirmed that the
380 hepatotoxicity of treatment activity compounds was low and TMP in LCE-PLA could
381 produce a better curative effect.

382 **4 Conclusions**

383 In the present study, LCE-PLA were synthesized and characterized. The
384 proposed LCE-PLA EE was more than 80.00%, and the duration prolonged nearly
385 5-fold compared with the naked LCE. *In vitro* cytotoxicity assay and *in vivo*
386 hepatoprotective effect confirmed that LCE-PLA enhanced the solubility and
387 bioavailability of active compounds, even declined the cytotoxicity of LCE. Overall,
388 these findings indicated that release microspheres can be a useful way to improve the
389 *Ligusticum chuanxiong* clinical use. Furthermore, this study can provide a promising
390 novel way to enhance the efficacy of short half-life ingredients.

391 Ethics statement

392 In current study, all animal experimental procedures followed the National
393 Institutes of Health guide for care and use of Laboratory animal (NIH Publications,
394 No.8023, revised 1978), and they were performed in strict accordance with the China
395 legislation regarding the use and care of laboratory animal. The present experiment
396 was approved by the Welfare and Ethics Committee of Fuzhou General Hospital of
397 Nanjing Military Command (No. IACUC-2018-0009).

398 Declaration of competing interest

399 The manuscript has been reviewed and approved by all authors. All authors
400 declare no conflict of interest.

401 Acknowledgements

402 This research was financially supported by the National Natural Science
403 Foundation of China (No. 31201350); and Natural Science Foundation of Fujian
404 Province (No. 2016J01105). We would like to express gratitude to all those who made
405 it possible to complete this manuscript.

407 **References**


- 408 Bagheri-Khoulenjani, S., Etrati-Khosroshahi, M., & Mirzadeh, H. (2010). Particle
409 Size and Distribution Modelling of Nanohydroxyapatite-in-gelatin
410 Nanocomposite Microspheres by Surface Response Method. *Iranian Polymer
411 Journal*, *19*(10), 743-755.
412 <https://doi.org/www.researchgate.net/publication/235928323>
- 413 Bezan, A., Mrcic, E., Krieger, D., Stojakovic, T., Pummer, K., Zigeuner, R., Hutterer,
414 G. C., & Pichler, M. (2015). The Preoperative AST/ALT (De Ritis) Ratio
415 Represents a Poor Prognostic Factor in a Cohort of Patients with
416 Nonmetastatic Renal Cell Carcinoma. *J Urol*, *194*(1), 30-35.
417 <https://doi.org/10.1016/j.juro.2015.01.083>
- 418 Bodmeier, R., Wang, J., & Bhagwatwar, H. (1992). Process and formulation variables
419 in the preparation of wax microparticles by a melt dispersion technique. II.
420 W/O/W multiple emulsion technique for water-soluble drugs. *J
421 Microencapsul*, *9*(1), 99-107. <https://doi.org/10.3109/02652049209021227>
- 422 Brodziak-Dopierala, B., Fischer, A., Szczelina, W., & Stojko, J. (2018). The Content
423 of Mercury in Herbal Dietary Supplements. *Biol Trace Elem Res*, *185*(1),
424 236-243. <https://doi.org/10.1007/s12011-018-1240-2>
- 425 Campardelli, R., Oleandro, E., & Reverchon, E. (2016). Supercritical assisted
426 injection in a liquid antisolvent for PLGA and PLA microparticle production.
427 *Powder Technology*, *287*, 12-19. <https://doi.org/10.1016/j.powtec.2015.09.035>
- 428 Chen, J. C., Tian, J. J., Ge, H. F., Liu, R. H., & Xiao, J. B. (2017). Effects of
429 tetramethylpyrazine from Chinese black vinegar on antioxidant and
430 hypolipidemia activities in HepG2 cells. *Food and Chemical Toxicology*, *109*,
431 930-940. <https://doi.org/10.1016/j.fct.2016.12.017>
- 432 Chu, I. M., Liu, T., & Chen, Y. (2018). Preparation and characterization of sustained
433 release system based on polyanhydride microspheres with core/shell-like
434 structures. *Journal of Polymer Research*, *26*(1), 1-6.
435 <https://doi.org/10.1007/s10965-018-1657-5>
- 436 Coowanitwong, I., Arya, V., Kulvanich, P., & Hochhaus, G. (2008). Slow release
437 formulations of inhaled rifampin. *Aaps Journal*, *10*(2), 342-348.
438 <https://doi.org/10.1208/s12248-008-9044-5>
- 439 Duan, Y., Zhang, B., Chu, L., Tong, H. H., Liu, W., & Zhai, G. (2016). Evaluation in
440 vitro and in vivo of curcumin-loaded mPEG-PLA/TPGS mixed micelles for
441 oral administration. *Colloids Surf B Biointerfaces*, *141*, 345-354.

- 442 <https://doi.org/10.1016/j.colsurfb.2016.01.017>
- 443 Feng, S. S., & Huang, G. F. (2001). Effects of emulsifiers on the controlled release of
444 paclitaxel (Taxol) from nanospheres of biodegradable polymers. *Journal of*
445 *Controlled Release*, 71(1), 53-69.
446 [https://doi.org/10.1016/S0168-3659\(00\)00364-3](https://doi.org/10.1016/S0168-3659(00)00364-3)
- 447 Ford Versypt, A. N., Pack, D. W., & Braatz, R. D. (2013). Mathematical modeling of
448 drug delivery from autocatalytically degradable PLGA microspheres--a
449 review. *Journal of Controlled Release*, 165(1), 29-37.
450 <https://doi.org/10.1016/j.jconrel.2012.10.015>
- 451 Gao, H. Y. (2013). Anti-hepatic fibrosis effects of traditional Chinese medicine: A
452 review. *Oapublishinglondon Com*, 1(1), 1-7.
453 <https://doi.org/10.13172/2052-787X-1-1-856>
- 454 Garlotta, D. (2001). A literature review of poly (lactic acid). *Journal of Polymers and*
455 *the Environment*, 9(2), 63-84. <https://doi.org/10.1023/A:1020200822435>
- 456 Ge, H., Chen, Y., Chen, J., Tian, J., Liang, X., & Chen, L. (2018). Evaluation of
457 antioxidant activities of ethanol extract from Ligusticum subjected to in-vitro
458 gastrointestinal digestion. *Food & Chemical Toxicology*, 119, 417-424.
459 <https://doi.org/10.1016/j.fct.2017.12.035>
- 460 Guo, W. L., Pan, Y. Y., Li, L., Li, T. T., Liu, B., & Lv, X. C. (2018). Ethanol extract
461 of Ganoderma lucidum ameliorates lipid metabolic disorders and modulates
462 the gut microbiota composition in high-fat diet fed rats. *Food & Function*,
463 9(6), 3419-3431. <https://doi.org/10.1039/C8FO00836A>
- 464 Khattab, A., & Zaki, N. (2017). Optimization and Evaluation of Gastroretentive
465 Ranitidine HCl Microspheres by Using Factorial Design with Improved
466 Bioavailability and Mucosal Integrity in Ulcer Model. *AAPS PharmSciTech*,
467 18(4), 957-973. <https://doi.org/10.1208/s12249-017-0744-y>
- 468 Lee, H., Lee, S. E., Byun, S. S., Kim, H. H., Kwak, C., & Hong, S. K. (2017). De
469 Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant
470 prognostic factor after surgical treatment in patients with clear-cell localized
471 renal cell carcinoma: a propensity score-matched study. *Bju International*,
472 119(2), 261. <https://doi.org/10.1111/bju.13545>
- 473 Li, H., Wang, Q., Yu, X., Bao, C., & Li, W. (2013). 25-Hydroxyvitamin D3-Loaded
474 PLA Microspheres: In Vitro Characterization and Application in Diabetic
475 Periodontitis Models. *AAPS PharmSciTech*, 14(2), 880.
476 <https://doi.org/10.1208/s12249-013-9978-5>

- 477 Li, Y., Song, P., Zhu, Q., Yin, Q. Y., Ji, J. W., Li, W., & Bian, H. M. (2014).
478 Liguzinediol improved the heart function and inhibited myocardial cell
479 apoptosis in rats with heart failure. *Acta pharmacologica Sinica*, 35(10),
480 1257-1264. <https://doi.org/10.1038/aps.2014.75>
- 481 Lin, Q., Huo, Q., Qin, Y., Zhao, Z., & Tao, F. (2017). Development of ligustrazine
482 hydrochloride carboxymethyl chitosan and collagen microspheres:
483 Formulation optimization, characterization, and vitro release. *Bioengineered*,
484 8(1), 55-60. <https://doi.org/10.1080/21655979.2016.1227584>
- 485 Ma, W. J., Yuan, X. B., Kang, C. S., Su, T., Yuan, X. Y., Pu, P. Y., & Sheng, J.
486 (2008). Evaluation of blood circulation of polysaccharide surface-decorated
487 PLA nanoparticles. *Carbohydrate Polymers*, 72(1), 75-81.
488 <https://doi.org/10.1016/j.carbpol.2007.07.033>
- 489 Mager, D. R., Iniguez, I. R., Gilmour, S., & Yap, J. (2015). The effect of a low
490 fructose and low glycemic index/load (FRAGILE) dietary intervention on
491 indices of liver function, cardiometabolic risk factors, and body composition
492 in children and adolescents with nonalcoholic fatty liver disease (NAFLD).
493 *JPEN J Parenter Enteral Nutr*, 39(1), 73-84.
494 <https://doi.org/10.1177/0148607113501201>
- 495 Metters, A., Anseth, K., & Bowman, C. (2000). Fundamental studies of a novel,
496 biodegradable PEG-b-PLA hydrogel. *Polyme*, 41(11), 3993-4004.
- 497 Mlalila, N., Swai, H., Kalombo, L., & Hilonga, A. (2014). Effects of spray-drying on
498 w/o/w multiple emulsions prepared from a stearic acid matrix. *Nanotechnol
499 Sci Appl*, 7, 105-112. <https://doi.org/10.2147/NSA.S72083>
- 500 Mo, Z. Z., Liu, Y. H., Li, C. L., Xu, L. Q., Wen, L. L., Xian, Y. F., Lin, Z. X., Zhan,
501 J. Y. X., Chen, J. N., Xu, F. F., & Su, Z. R. (2017). Protective Effect of
502 SFE-CO₂ of Ligusticum chuanxiong Hort Against D-Galactose-Induced
503 Injury in the Mouse Liver and Kidney. *Rejuvenation Research*, 20(3),
504 231-243. <https://doi.org/10.1089/rej.2016.1870>
- 505 Murphy, N. P., & Lampe, K. J. (2018). Fabricating PLGA microparticles with high
506 loads of the small molecule antioxidant N-acetylcysteine that rescue
507 oligodendrocyte progenitor cells from oxidative stress. *Biotechnology and
508 Bioengineering*, 115(1), 246-256. <https://doi.org/10.1002/bit.26443>
- 509 Patrick, B. O. D., & James, W. M. (1997). Preparation of microspheres by the solvent
510 evaporation technique. *Advanced Drug Delivery Reviews*, 28(1), 25-42.
511 [https://doi.org/10.1016/S0169-409X\(97\)00049-5](https://doi.org/10.1016/S0169-409X(97)00049-5)

- 512 Petkar, K. C., Chavhan, S., Kunda, N., Saleem, I., Somavarapu, S., Taylor, K. M. G.,
513 & Sawant, K. K. (2018). Development of Novel Octanoyl Chitosan
514 Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by
515 Factorial Design. *AAPS PharmSciTech*, 19(4), 1758–1772
516 <https://doi.org/10.1208/s12249-018-0972-9>
- 517 Pistner, H., Bendix, D. R., Mühling, J., & Reuther, J. F. (1993). Poly(L-lactide): a
518 long-term degradation study in vivo. Part III. Analytical characterization.
519 *Biomaterials*, 14(4), 291-298. [https://doi.org/10.1016/0142-9612\(93\)90121-H](https://doi.org/10.1016/0142-9612(93)90121-H)
- 520 Qin, C. J., Zhao, L. H., Zhou, X., Zhang, H. L., Wen, W., Tang, L., Zeng, M., Wang,
521 M. D., Fu, G. B., Huang, S., Huang, W. J., Yang, Y., Bao, Z. J., Zhou, W. P.,
522 Wang, H. Y., & Yan, H. X. (2018). Inhibition of dipeptidyl peptidase IV
523 prevents high fat diet-induced liver cancer angiogenesis by downregulating
524 chemokine ligand 2. *Cancer Lett*, 420, 26-37.
525 <https://doi.org/10.1016/j.canlet.2018.01.064>
- 526 Surwase, S. S., Munot, N. M., Idage, B. B., & Idage, S. B. (2017). Tailoring the
527 properties of mPEG-PLLA nanoparticles for better encapsulation and tuned
528 release of the hydrophilic anticancer drug. *Drug Delivery and Translational*
529 *Research*, 7(3), 416-427. <https://doi.org/10.1007/s13346-017-0372-9>
- 530 Wang, L. L., Li, Z., Zhao, X. P., Liu, W., Liu, Y. F., Yang, J. H., Li, X., Fan, X. H., &
531 Cheng, Y. Y. (2013). A Network Study of Chinese Medicine Xuesaitong
532 Injection to Elucidate a Complex Mode of Action with Multicompound,
533 Multitarget, and Multipathway. *Evidence-Based Complementary and*
534 *Alternative Medicine*, 1-8. <https://doi.org/10.1155/2013/652373>
- 535 Wu, H., Hu, Z., & Jin, T. (2016). Sustained-release microspheres of amifostine for
536 improved radio-protection, patient compliance, and reduced side effects. *Drug*
537 *Delivery*, 23(9), 3704. <https://doi.org/10.1080/10717544.2016.1223222>
- 538 Xu, H. L., Zhong, H. J., Liu, M. M., Xu, C. L., & Gao, Y. (2011).
539 Lappaconitine-loaded microspheres for parenteral sustained release: effects of
540 formulation variables and in vitro characterization. *Pharmazie*, 66(9),
541 654-661. <https://doi.org/10.1691/ph.2011.1042>
- 542 Yoon, H., & Liu, R. H. (2007). Effect of Selected Phytochemicals and Apple Extracts
543 on NF- κ B Activation in Human Breast Cancer MCF-7 Cells. *Journal of*
544 *Agricultural & Food Chemistry*, 55(8), 3167.
545 <https://doi.org/10.1021/jf0632379>
- 546 Yu, T., Guo, X., Zhang, Z., Liu, R., Zou, L., Fu, J., & Shi, Z. (2016). Meta-Analysis

- 547 of the Clinical Effectiveness and Safety of Ligustrazine in Cerebral Infarction.
 548 *Evid Based Complement Alternat Med*, 2016, 3595946.
 549 <https://doi.org/10.1155/2016/3595946>
- 550 Yuniarto, K., Purwanto, Y. A., Purwanto, S., Welt, B. A., Purwadaria, H. K., &
 551 Sunarti, T. C. (2016). Infrared and Raman studies on polylactide acid and
 552 polyethylene glycol-400 blend. In *AIP Conference Proceedings*, vol. 1725
 553 (pp. 020101): AIP Publishing.
- 554 Zhang, X., & Haque, Z. Z. (2015). Generation and stabilization of whey-based
 555 monodisperse nanoemulsions using ultra-high-pressure homogenization and
 556 small amphipathic co-emulsifier combinations. *J Agric Food Chem*, 63(45),
 557 10070-10077. <https://doi.org/10.1021/acs.jafc.5b03889>
- 558 Zou, Y. F., Fu, Y. P., Chen, X. F., Austarheim, I., Inngjerdingen, K. T., Huang, C.,
 559 Eticha, L. D., Song, X., Li, L., Feng, B., He, C. L., Yin, Z. Q., & Paulsen, B.
 560 S. (2017). Purification and Partial Structural Characterization of a
 561 Complement Fixating Polysaccharide from Rhizomes of *Ligusticum*
 562 *chuanxiong*. *Molecules*, 22(2), 287.
 563 <https://doi.org/10.3390/molecules22020287>
- 564



565

566

567 **Highlights**

- 568 ● Sustained-release microspheres encapsulation efficiency of TMP are more
 569 than 80%
- 570 ● LCE-PLA microspheres duration of efficacy prolong nearly 5-fold
- 571 ● LCE-PLA microspheres cytotoxicity declined 25% than naked LCE
- 572 ● LCE-PLA microspheres had a significant hepatoprotective effect

573

574

575 Credit Author Statement

576 Huifang Ge: Designed and participated the experiment, Writing-Original draft
577 preparation. Jicheng Chen: Designed the experiment and revised the manuscript and
578 was responsible for the supervision of the whole research. Peixuan Lin: participated in
579 the experiment and revision of the paper. Taiduan Luo: participated in the experiment
580 and analysis the experimental date. Zhiming Yan and Jianbo Xiao had provided
581 guidance for publication, and help revision the paper. Song Miao: Writing- Reviewing
582 and was responsible for the supervision of the whole research.

583 .

584

585 **Figures Captions**

586 **Figure 1** FI-RT of *Ligusticum chuanxiong* extraction (LCE), polylactic acid (PLA)
587 and *Ligusticum chuanxiong* extract-polylactic acid microspheres (LCE-PLA)


588 **Figure 2** SEM of *Ligusticum chuanxiong* extract-polylactic acid microspheres
589 (LCE-PLA) under different preparation technology. PVA, polyvinyl alcohol; DCM,
590 dichloromethane. A to E is the SEM of drug-loading microspheres. The samples were
591 observed using SEM with voltage 15 kV and 10000 x magnification. A is the
592 microspheres made on the situation of PLA 20 mg/mL (PLA/ DCM, m/v), PVA
593 0.80% (PVA / water, m/v), and shearing for 4 min at 9000 r/min; B changes the PLA
594 to 30 mg/mL (PLA/ DCM, m/v) based on A; C changes the PVA additive amount of
595 1.00% (PVA / water, m/v) compare to A; D the shearing force is changed to 10000
596 r/min; E changes the shear time to 6 min based on A.

597 **Figure 3** Swelling curves (A) and cumulative release (B) of *Ligusticum chuanxiong*
598 polylactic acid microspheres under different pH media (Mean \pm SD, n=3)

599 **Figure 4** Effect of *Ligusticum chuanxiong* extraction (LCE), *Ligusticum*
600 *chuanxiong*-polylactic acid (LCE-PLA) microspheres and pure tetramethylpyrazine
601 (TMP) on cytotoxicity in HepG2 cells (Mean \pm SD, n=3). In the present study, the
602 contents of TMP were equal in both LCE and LCE-PLA microspheres.


603 **Figure 5** Representative histological analysis of liver sections (A) and kidney sections
604 (B) from mice fed on NFD (normal-fat diet), HFD (High fat diet), HFD+S (HFD +
605 6.00 mg/kg B.w./Day *Simvastatin*), HFD+LCE (HFD +136.50 mg/kg B.w./Day
606 *Ligusticum chuanxiong* alcohol extract), HFD+DM (HFD +163.00 mg/kg B.w./Day
607 drug-loading microspheres) and drug-loading microspheres for 6 weeks and hepatic
608 total cholesterol (TC), triglyceride (TG), aspartate aminotransferase (ALT), alanine
609 aminotransferase (AST) levels in each group (C). Values are means \pm SD (n=8).
610 # p <0.05; ## p <0.01 means statistically significant difference compared to the NFD
611 group; * p <0.05; ** p <0.01 means statistically significant difference compared to the
612 HFD group.


614

615 **Figure 1**

616


618

619 **Figure 2**

621 **Figure 3**

622


624

625 **Figure 4**

626

628

629 **Figure 5**



630

631

632 **Table**

633 **Table 1** Impact of NFD, HFD, Simvastatin, TMP and LCE supplementation on
 634 alteration of body and organ weights of KM mice (means ± SD, n=8)

Group	NFD	HFD	Δa (%)	HFD+S		HFD+LCE		HFD+DM		Δd1 (%)	Δd2 (%)
				Δb1 (%)	Δb2 (%)	Δc1 (%)	Δc2 (%)				
up											

Weight (g)	Initial	Final	Gain	Liver	Kidney	Adipose	Visceral	Subcutaneous	Intestine	Spleen	Heart	Brain
Initial	20.42	20.49	0.3	20.36	-0.2	-0.6	20.99	2.70	2.38	20.54	0.58	0.24
Final	±0.79	±0.55	4	±0.66	9	0	±1.13			±0.50		
Final	40.73	46.66	12.70	38.28	-6.4	-21.89	37.69	-8.0	-23.7	37.64	-8.2	-23.96
Final	±2.67	±2.63	70	±2.81	0	89	±2.17	7	80	±2.07	1	96
Gain	20.31	26.17	28.85	17.92	-11.77	-31.52	16.70	-17.77	-36.19	17.13	-15.66	-34.54
Gain	±2.48	±2.39	85	±2.28	77	52	±2.66	77	19	±2.13	66	54
Liver	2.01±	2.64±	31.34	2.22±	10.4	-15.5	2.51±	24.8	-4.9	2.24±	11.4	-15.15
Liver	0.18	0.26	34	0.32	5	91	0.22	8	2	0.19	4	15
Kidney	0.41±	0.65±	58.53	0.41±	0.00	-36.92	0.41±	0.00	-36.92	0.41±	0.00	-36.92
Kidney	0.05	0.09	53	0.04			0.05			0.03		92

635 Notes: NFD: normal-fat diet; HFD: High fat diet; HFD+S: High fat diet + 6 mg/kg B.w./Day
 636 simvastatin; HFD+LCE: High fat diet +136.5 mg/kg B.w./day *Liguticum chuanxiong* alcohol
 637 extract; HFD+DM: High fat diet +163 mg/kg B.w./day drug-loading microspheres.

638 Δa difference between NFD and HFD;
 639 $\Delta b1$ difference between NFD and HFD +S;
 640 $\Delta b2$ difference between HFD and HFD +S;
 641 $\Delta c1$ difference between NFD and HFD + LCE;
 642 $\Delta c2$ difference between HFD and HFD + LCE;
 643 $\Delta d1$ difference between NFD and HFD + DM;
 644 $\Delta d2$ difference between HFD and HFD + DM.

645